A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 06 Oct 2025
At a glance
- Drugs Xaluritamig (Primary) ; Xaluritamig (Primary) ; Abiraterone; Enzalutamide
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Amgen
Most Recent Events
- 17 Sep 2025 Planned number of patients changed from 461 to 479.
- 17 Sep 2025 Planned End Date changed from 17 Aug 2028 to 4 Mar 2032.
- 17 Sep 2025 Planned primary completion date changed from 14 Feb 2026 to 5 Mar 2030.